GVHD
Advertisement
The study evaluated the safety and efficacy of ruxolitinib for treating chronic graft-versus-host disease after allo-HSCT.
Partially hydrolyzed guar gum, a soluble dietary fiber obtained from guar beans, was evaluated due to its butyrate content.
The Lee Symptom Scale for skin sclerosis was informed by patient interviews and feedback.
Patients with cGVHD appreciate the opportunity to connect with other individuals also navigating a cGVHD diagnosis.
Access to a multidisciplinary GVHD clinic with telehealth abilities improved care for patients with acute and chronic GVHD.
Learn how oral dysbiosis correlates with exacerbated cGVHD in patients after receiving hematopoietic cell transplantation.
Novel agents recently approved by the FDA showed promising responses when combined for treating refractory cGVHD.
The study highlights the need for improved patient education and provider communication on early symptoms of cGVHD.
Research presented at ASH 2024 highlighted the importance of absolute monocyte counts after transplant.
Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ...
A study presented at the 2024 ASH Annual Meeting suggests that a certain test may predict GI issues caused by GVHD.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
The study highlighted that adding abatacept to CNI/MTX-based GVHD prophylaxis showed durable central outcomes post-HCT.
Kirk R. Schultz, MD, FCAHS, explains that multiple strategies for GVHD prevention and preemption are under investigation.
Risk factors for GVHD and its severity differ by donor type following allogeneic SCT with post-transplant PTCy prophylaxis.
Patients with pulmonary comorbidities and a history of smoking are at increased risk for chronic GVHD.
Piyanuch Kongtim, MD, PhD, shares insights from work she presented at the 2024 ASH Annual Meeting.
Irwin Walker, MBBS, joined Cancer Nursing Today at ASH 2024 to share his insights on the pilot trial and the next steps.
Patient-reported outcomes increased the risk of health care utilization and HCT-related complications, like GVHD, post HCT.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.